Bausch Health Companies Inc. Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31)
Bausch Health Companies Inc. (BHC) reported Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) of $504.59 million for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseRemainderOfFiscalYear · last filed 2011-11-04
- Bausch Health Companies Inc. future amortization expense, remainder of fiscal year (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$64.00M.
| Period end | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 3 month | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 6 month | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 9 month |
|---|---|---|---|
| 2011-09-30 | -$64.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $504.59M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $568.59M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |